Intellectual property « Science and Enterprise

National Science Foundation is funding a new system that uses artificial intelligence to find optimal combinations… https://t.co/jbZAJqQpmT
about 22 hours ago
New post on Science and Enterprise: NSF Funds AI Covid-19 Drug Combo Simulation https://t.co/j7DsIncCUk #Science #Business
about 22 hours ago
A spin-off enterprise from academic labs is raising $125 million for genetically edited pigs to produce organs for… https://t.co/CVwEr6dEoU
about 22 hours ago
New post on Science and Enterprise: Gene-Edited Transplant Organ Company Raises $125M https://t.co/UYlUcA8Z5X #Science #Business
about 1 day ago
A home Covid-19 test is being evaluated with a smartphone app, as part of an NIH program to quickly develop Covid-1… https://t.co/82gYsU3rvr
about 2 days ago

AbbVie Licenses Engineered Crispr Cell Process

By Alan, on February 10th, 2021%

Drug maker AbbVie is acquiring a technology using the gene-editing process Crispr to produce new off-the-shelf engineered T-cells as disease therapies. . . . → Read More: AbbVie Licenses Engineered Crispr Cell Process

Cancer Immunotherapy Adapted for HIV

By Alan, on February 1st, 2021%

A biotechnology company is adapting and licensing its immunotherapy process, originally designed for cancer, as a cure for HIV infections. . . . → Read More: Cancer Immunotherapy Adapted for HIV

Institutions Join Global Health Breakthrough Network

By Alan, on January 28th, 2021%

Wellcome Leap aims to establish a model for faster design and development of health breakthroughs, beginning with elimination of administrative obstacles. . . . → Read More: Institutions Join Global Health Breakthrough Network

Universities Form Joint Engineering Patent Pool

By Alan, on January 15th, 2021%

A group of 15 American universities are putting part of their engineering patents into a common licensing pool for commercial development. . . . → Read More: Universities Form Joint Engineering Patent Pool

Biotech Licenses mRNA Technology for Aging

By Alan, on January 13th, 2021%

A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging. . . . → Read More: Biotech Licenses mRNA Technology for Aging

Drug Maker Gains Access to Hidden Protein Immunotherapies

By Alan, on January 12th, 2021%

Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells. . . . → Read More: Drug Maker Gains Access to Hidden Protein Immunotherapies

AbbVie Acquires Coronavirus Antibody Therapy

By Alan, on December 15th, 2020%

Drug maker AbbVie is licensing a synthetic antibody to treat Covid-19 and SARS coronaviruses that the company began funding in June. . . . → Read More: AbbVie Acquires Coronavirus Antibody Therapy

Biotech Licenses Precision Cancer Biologic to Genentech

By Alan, on December 14th, 2020%

A biotechnology company discovering synthetic proteins that target cancer-causing genetic mutations is licensing its lead product to biologics maker Genentech. . . . → Read More: Biotech Licenses Precision Cancer Biologic to Genentech

Bayer Gains Lung Cancer Therapy in $670M Deal

By Alan, on December 7th, 2020%

Global drug maker Bayer AG is licensing an engineered T-cell therapy to treat mesothelioma and other solid tumor cancers from biotech Atara Biotherapeutics. . . . → Read More: Bayer Gains Lung Cancer Therapy in $670M Deal

Stem Cell Respiratory Therapy Licensed in $1.4B Deal

By Alan, on November 20th, 2020%

Global drug maker Novartis is acquiring a stem cell-based treatment for a serious respiratory disease associated with Covid-19 infections. . . . → Read More: Stem Cell Respiratory Therapy Licensed in $1.4B Deal

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise